-
Mashup Score: 2Webprogram Unavailable - 1 month(s) ago
Please click HERE if you are not redirected in 5
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf
-
-
Mashup Score: 18
Program: Late-breaking Abstracts Session: Late-Breaking Abstracts Session Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphomas, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Diseases, Lymphoid Malignancies 1 Medica l College of Wisconsin, Milwaukee, WI 2 Dana-Farber Cancer Institute / ECOG-ACRIN Biostatistics, Bostin, MA 3 Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 4 Emory University / Winship Cancer Institute, Atlanta, GA 5 University of
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Stop ASCT for MCL...another evidence https://t.co/MyUi5Xj692
-
-
Mashup Score: 7
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA Hematology Disease Topics & Pathways: Research, Clinical trials, Bispecific Antibody Therapy, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Adverse Events Elena Zamagni, MD 1 *, Tobias Silzle, MD 2 *, Ivan Špička 3 *, Sabrin Tahri, MD 4 *, Sarah Lonergan 4 *, Inger S. Nijhof, MD, PhD 5 *, Antonietta Pia Falcone,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 1️⃣0️⃣ Majestec-4/EMN30 Trial ➡️ https://t.co/gAOFjnxR4S ✅Multiple cohorts comparing Tec alone, Tec-Len vs Len alone post ASCT- time limited maintenance in all pts Will be interesting to see if intensifying maintenance for 2 yrs will improve efficacy/safety https://t.co/KclSGJQAU1
-
-
Mashup Score: 10
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Adverse Events, Monoclonal Antibody Therapy, Study Population, Human Meletios-Athanasios Dimopoulos 1, Peter M. Voorhees, MD 2, Fredrik Schjesvold, MD,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 3️⃣ AQUILA study ➡️ https://t.co/cBxHkGczl9 ✅ Dara vs active monitoring in smoldering myeloma ✅ n=390, median F/U: 5.5 yrs ✅ORR in 2/3 of pts 🛑one third of Dara pts received second line ttt Data on progression events will be imp https://t.co/jlYZOAaqNv
-
-
Mashup Score: 12
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research Vania Hungria, MD, PhD 1, Pawel Robak, MD, PhD 2 *, Marek Hus, MD, PhD 3 *, Vera Zherebtsova, MD 4 *, Christopher Ward, MD, PhD 5 *, Phoebe Joy Ho, MBBS 6, Roman Hajek, MD, PhD 7, Kihyun Kim, MD 8 *, Sebastian Grosicki, MD, PhD 9 *, Hanlon Sia, MBBS FRACP FRCPA
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 4️⃣ DREAMM-7 OS ➡️ https://t.co/UeHKF6RUbK ✅ median OS was NR in either arm at first interim analysis, a trend in favor of BVd vs DVd, with an HR of 0.57 noted - Will see OS second interim analysis Make case of possible benefit of early BCMA based ttt(BsAb maybe) https://t.co/rovJLAHVYV
-
-
Mashup Score: 5
Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf
-
-
Mashup Score: 11
Program: Oral and Poster Abstracts Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, Adult, Epidemiology, Clinical Research, Health outcomes research, Education, Diseases, Real-world evidence, Myeloid Malignancies, Study Population, Human 1 Morsani College of Medicine, University of South Florida, Tampa, FL 2 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 3 Department of Malignant Hematology, H. Lee Moffitt
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, Ziad Abuhelwa, MD (@zabuhelwa) discusses a retrospective analysis of the outcomes of a large cohort of MDS patients to compare outcomes between IDH1-MT and wild-type. Read more: https://t.co/pL3aNqTTF8 @ASH_hematology #ASH24 https://t.co/IyebaSFPpl
-
-
Mashup Score: 6Paper: The Differential Effects of Bridging Therapy on Immune Microenvironment and Outcomes with Idecabtagene-Vicleucel in Multiple Myeloma - 3 month(s) ago
Program: Oral and Poster Abstracts Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III Hematology Disease Topics & Pathways: Research, Adult, Translational Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, Diseases, Immune mechanism, Biological therapies, Treatment Considerations, Lymphoid Malignancies, Computational biology, Biological Processes, Study Population, Human Praneeth Reddy Sudalagunta, PhD 1 *, David R. Noyes, MS 2 *,
Source: ash.confex.comCategories: General Medicine News, Onc News and JournalsTweet-
Join Praneeth Reddy Sudalagunta, PhD at #ASH24 as he presents the differential effects of bridging therapy on the immune microenvironment and outcomes with idecabtagene-vicleucel in multiple myeloma. Read more: https://t.co/148u07T4t4 @ASH_hematology #MoffittASH24 https://t.co/BIWku7TiPA
-
-
Mashup Score: 9
Program: Oral and Poster Abstracts Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III Hematology Disease Topics & Pathways: Research, Clinical Research, Real-world evidence Abida Babu, MBBS 1, Kathryn Bower, MD 2 *, Madiha Siraj, MD 3 *, Biwei Cao, MS 4 *, Jongphil Kim, PhD 2 *, Hany Elmariah, MD, MS 5, Rawan Faramand, MD 5, Sayeef Mirza, MD, MPH 5, Lia Perez, MD 5 *, Asmita Mishra, MD, MBA 5, Farhad Khimani, MD 5 *, Jose L. Ochoa-Bayona, MD 1 *,
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
Join Abida Babu, MBBS as she discusses the effect of fludarabine and melphalan educed-intensity conditioning in comparison to fludarabine and busulfan myeloablative on allogeneic hematopoietic cell transplantation in AML in complete remission. Read more: https://t.co/ZN57Hqmz3w… https://t.co/wQhFMOFsrG https://t.co/bbm0yiAQYb
-
Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM [Dec 11, 2022] Konishi et al. @IreneGhobrial Abs 3184 #ASH22 https://t.co/JURrogtY9g #COVID19Vaccine #mmsm #IDonc #COVID19nCancer HT @CyclingDoctor cc @COVID19nCCC